[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK1294369T3 - Hidtil ukendte formuleringer med alfa-2,4-disulfophenyl-N-tert-bytylnitron - Google Patents

Hidtil ukendte formuleringer med alfa-2,4-disulfophenyl-N-tert-bytylnitron

Info

Publication number
DK1294369T3
DK1294369T3 DK01934785T DK01934785T DK1294369T3 DK 1294369 T3 DK1294369 T3 DK 1294369T3 DK 01934785 T DK01934785 T DK 01934785T DK 01934785 T DK01934785 T DK 01934785T DK 1294369 T3 DK1294369 T3 DK 1294369T3
Authority
DK
Denmark
Prior art keywords
disulfophenyl
tert
alpha
new formulations
butyl nitrone
Prior art date
Application number
DK01934785T
Other languages
Danish (da)
English (en)
Inventor
Patrik Eriksson
Mats J Andersson
Mattias Andersson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of DK1294369T3 publication Critical patent/DK1294369T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK01934785T 2000-05-23 2001-05-22 Hidtil ukendte formuleringer med alfa-2,4-disulfophenyl-N-tert-bytylnitron DK1294369T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0001916A SE0001916D0 (sv) 2000-05-23 2000-05-23 Novel formulation

Publications (1)

Publication Number Publication Date
DK1294369T3 true DK1294369T3 (da) 2005-11-14

Family

ID=20279797

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01934785T DK1294369T3 (da) 2000-05-23 2001-05-22 Hidtil ukendte formuleringer med alfa-2,4-disulfophenyl-N-tert-bytylnitron

Country Status (30)

Country Link
US (2) US20030181527A1 (no)
EP (1) EP1294369B1 (no)
JP (1) JP3744857B2 (no)
KR (1) KR20030001545A (no)
CN (1) CN1268326C (no)
AR (1) AR030218A1 (no)
AT (1) ATE303803T1 (no)
AU (2) AU2001260935B2 (no)
BR (1) BR0111055A (no)
CA (1) CA2408781A1 (no)
CZ (1) CZ20023849A3 (no)
DE (1) DE60113255T2 (no)
DK (1) DK1294369T3 (no)
EE (1) EE200200653A (no)
ES (1) ES2247112T3 (no)
HK (1) HK1051649A1 (no)
HU (1) HUP0302310A3 (no)
IL (1) IL152533A0 (no)
IS (1) IS6610A (no)
MX (1) MXPA02011533A (no)
MY (1) MY130445A (no)
NO (1) NO20025461D0 (no)
NZ (1) NZ522329A (no)
PL (1) PL361284A1 (no)
RU (1) RU2271800C2 (no)
SE (1) SE0001916D0 (no)
SK (1) SK16542002A3 (no)
TW (1) TWI259078B (no)
WO (1) WO2001089507A1 (no)
ZA (1) ZA200208747B (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050182060A1 (en) * 2004-02-13 2005-08-18 Kelly Michael G. 2-Substituted and 4-substituted aryl nitrone compounds
US10005830B2 (en) 2009-03-05 2018-06-26 Ablynx N.V. Antigen binding dimer-complexes, methods of making/avoiding and uses thereof
US9265834B2 (en) 2009-03-05 2016-02-23 Ablynx N.V. Stable formulations of polypeptides and uses thereof
EP2470015B1 (en) 2009-08-24 2016-01-13 Hough Ear Institute Nitrone compounds for treating sensorineural hearing loss
LT2805731T (lt) * 2009-09-03 2019-02-11 Ablynx N.V. Stabilios polipeptidų kompozicijos ir jų panaudojimas
EP2512489A4 (en) * 2009-12-15 2014-04-02 Merck Sharp & Dohme METHOD OF PREPARING ACADESINE
AU2012211989B2 (en) * 2011-02-04 2017-03-02 Hough Ear Institute Methods for treating brain injury
EP2911648B1 (en) * 2012-10-25 2017-02-01 Fresenius Kabi Oncology Limited Stable pharmaceutical composition of 5-aza-2'peoxyotipine
US10660851B2 (en) 2015-01-02 2020-05-26 Rxos Medical Polyfunctional radical scavenger hydrogel formulation
CN116650411A (zh) * 2022-02-25 2023-08-29 广州喜鹊医药有限公司 一种注射用硝酮嗪药物组合物及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR960008230B1 (ko) * 1989-10-17 1996-06-21 윌리엄 쥐.씨먼 중추신경계의 산화적 손상에 관련된 질병들을 억제하기 위한 조성물들
JP2813023B2 (ja) * 1990-03-13 1998-10-22 株式会社神戸製鋼所 Ｍｉｓ型ダイヤモンド電界効果トランジスタ
US5488145A (en) * 1993-12-23 1996-01-30 Oklahoma Medical Research Foundation 2,4-disulfonyl phenyl butyl nitrone, its salts, and their use as pharmaceutical free radical traps

Also Published As

Publication number Publication date
CZ20023849A3 (cs) 2003-05-14
KR20030001545A (ko) 2003-01-06
US20080161406A1 (en) 2008-07-03
JP2003534276A (ja) 2003-11-18
SE0001916D0 (sv) 2000-05-23
AU2001260935B2 (en) 2005-05-19
DE60113255T2 (de) 2006-06-08
NO20025461L (no) 2002-11-14
CN1268326C (zh) 2006-08-09
ES2247112T3 (es) 2006-03-01
IS6610A (is) 2002-11-11
RU2271800C2 (ru) 2006-03-20
TWI259078B (en) 2006-08-01
CN1430510A (zh) 2003-07-16
NO20025461D0 (no) 2002-11-14
NZ522329A (en) 2004-07-30
BR0111055A (pt) 2003-04-15
JP3744857B2 (ja) 2006-02-15
ATE303803T1 (de) 2005-09-15
CA2408781A1 (en) 2001-11-29
PL361284A1 (en) 2004-10-04
EE200200653A (et) 2004-06-15
RU2002129588A (ru) 2004-03-27
WO2001089507A1 (en) 2001-11-29
MY130445A (en) 2007-06-29
HK1051649A1 (en) 2003-08-15
MXPA02011533A (es) 2003-04-25
EP1294369A1 (en) 2003-03-26
SK16542002A3 (sk) 2003-04-01
HUP0302310A2 (hu) 2003-11-28
AU6093501A (en) 2001-12-03
EP1294369B1 (en) 2005-09-07
DE60113255D1 (de) 2005-10-13
AR030218A1 (es) 2003-08-13
ZA200208747B (en) 2004-02-10
US20030181527A1 (en) 2003-09-25
HUP0302310A3 (en) 2005-06-28
IL152533A0 (en) 2003-05-29

Similar Documents

Publication Publication Date Title
NO20023616D0 (no) Ny anvendelse
NO20031483L (no) Vaksine
NO20026175L (no) Vaksinesammensetning
EE200200387A (et) Fulvestrandi formulatsioonid
NO20024172L (no) Vaksine
NO20024170D0 (no) Forminsket, nållös injektor
ATE391531T1 (de) Schweisshemmende mittel
ATE393614T1 (de) Enganliegende, flüssigkeitsaustritt- widerstandsfähige damenbinde
DK1294369T3 (da) Hidtil ukendte formuleringer med alfa-2,4-disulfophenyl-N-tert-bytylnitron
NO20001294D0 (no) Måler for skyvekraft
DE60133976D1 (de) Turbomaschinen
NO20030868D0 (no) N-(3,5-diklor-2-metoksyfenyl)-4-metoksy-3-piperazin-1-yl- benzensulfonamid
DE10196460T1 (de) Selbstzerstör-Spritze
ATE270044T1 (de) Fungizide formulierung
ATE268116T1 (de) Mesotrion-formulierungen
DE60125927D1 (de) Impfstoffe gegen hiv
DE50114606D1 (de) Schalungsmaterial
IT249372Y1 (it) Struttura perfezionata di gancio.
IT250210Y1 (it) Scudetto
SE0004580D0 (sv) Leveranspunkt
SE0000645D0 (sv) New pharmaceutically active compounds
ITPR20000011A0 (it) Barella
DK1267849T3 (da) Begrænsning af genoptagelse af lægemiddelanvendelse
SE0001240D0 (sv) Injektionsspruta
UA4638S (uk) Шприц